Recruiting

3

688

RoW

Radical colectomy, HIPEC, Systemic chemotherapy

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University

Colorectal Cancer

04/24

04/26

Recruiting

N/A

200000

RoW

Beijing Friendship Hospital, Beijing YouAn Hospital, The First Hospital of Jilin University, Henan Provincial People's Hospital, Beijing Ditan Hospital, First Affiliated Hospital of Xinjiang Medical University, LanZhou University, The Second Affiliated Hospital of Chongqing Medical University, West China Hospital, Taiyuan No.3 Hospital, Hebei Medical University Third Hospital, Shengjing Hospital, Tianjin Third Central Hospital, Peking University First Hospital, Peking Union Medical College Hospital, The Affiliated Hospital Of Southwest Medical University, Shanghai Public Health Clinical Center, Ruijin Hospital, First Affiliated Hospital Xi'an Jiaotong University, Xiangya Hospital of Central South University, Beijing Tiantan Hospital, Wuhan University, The First Affiliated Hospital of Kunming Medical College, The Affiliated Hospital of Xuzhou Medical University, The Affiliated Hospital of Yanbian University, First Affiliated Hospital of Chongqing Medical University, The Fouth Hospital of Qinghai province, Weifang Medical University, Hunan Provincial People's Hospital, The Second Hospital of Hebei Medical University, Xixi Hospital of Hangzhou, General Hospital of Ningxia Medical University, Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Peking University People's Hospital, Nanfang Hospital of Southern Medical University, The Affiliated Hospital Of Guizhou Medical University, Guizhou Provincial People's Hospital, Hainan General Hospital, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Fifth Hospital of Shijiazhuang City, Yan'an University Affiliated Hospital, Infectious Disease Hospital of Wuhai, Logistics University of Chinese People's Armed Police Forces, People's Hospital of Changji Hui Autonomous Prefecture，Xinjiang

Chronic Hepatitis B

12/22

12/25

Recruiting

N/A

12000

RoW

no intervention

Zhujiang Hospital, National Natural Science Foundation of China

Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism

12/24

12/25

Completed

3

336

Canada, RoW

Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2

Reistone Biopharma Company Limited

Atopic Dermatitis

08/22

05/23

Recruiting

3

510

RoW

611, Matching placebo

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Dermatitis, Atopic

09/25

05/26

Recruiting

3

472

RoW

PG-011Gel, PG-011Gel 3%, Vehicle, placebo

Prime Gene Therapeutics Co., Ltd.

Atopic Dermatitis

12/24

01/26

Active, not recruiting

3

747

RoW

JS005 (recombinant humanized monoclonal antibody against IL-17A)

Shanghai Junshi Bioscience Co., Ltd.

Moderate to Severe Chronic Plaque Psoriasis

08/25

10/25

Recruiting

3

400

RoW

611, Placebo, Topical corticosteroid

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Dermatitis, Atopic, Eczema, Atopic

10/25

08/26

Recruiting

3

351

RoW

Roflumilast Cream 0.15%, Vehicle cream

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Atopic Dermatitis (AD)

08/25

08/25

Completed

2

160

RoW

Placebo, HB0017, HB0017 dosing regimens

Huabo Biopharm Co., Ltd.

Plaque Psoriasis

05/23

01/24

Completed

2

160

RoW

CM310

Keymed Biosciences Co.Ltd

Atopic Dermatitis

07/24

07/24

Recruiting

2

129

RoW

ICP-488 Tablets, ICP-488 Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Moderate to Severe Plaque Psoriasis

10/24

11/24

Recruiting

2

199

Europe, Canada, Japan, US, RoW

GSK1070806, Placebo

GlaxoSmithKline

Dermatitis, Atopic

10/25

01/26

Not yet recruiting

1/2

260

NA

2mg QY201 tablets or 2mg QY201 placebo,BID, 5mg QY201 tablets or 5mg QY201 placebo,BID, 10mg QY201 tablets or 10mg QY201 placebo,QD, 10mg QY201 tablets or 10mg QY201 placebo,BID, 15mg QY201 tablets or 15mg QY201 placebo,BID, 20mg QY201 tablets or 20mg QY201 placebo,BID, 5mg QY201 tablets，BID, 10mg QY201 tablets，BID, 20mg QY201 tablets，BID, QY201 placebo，BID

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Atopic Dermatitis

12/25

12/25